title: Topical intranasal ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (Hexabrix) reduces the acute response to nasal challenge with allergen.
authors.forename: Shilpa
authors.initials: S
authors.lastname: Vishwanath
authors.forename: Fuad M
authors.initials: FM
authors.lastname: Baroody
authors.forename: Mohamad R
authors.initials: MR
authors.lastname: Chaaban
authors.forename: Marcella
authors.initials: M
authors.lastname: deTineo
authors.forename: Kenneth H
authors.initials: KH
authors.lastname: Lasser
authors.forename: Elliot C
authors.initials: EC
authors.lastname: Lasser
authors.forename: Robert M
authors.initials: RM
authors.lastname: Naclerio
mesh_terms: D000281:Administration, Intranasal; D000485:Allergens; D018926:Anti-Allergic Agents; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006801:Humans; D007485:Ioxaglic Acid / Q000008:administration & dosage*; D009299:Nasal Provocation Tests; D006255:Rhinitis, Allergic, Seasonal / Q000517:prevention & control; D012912:Sneezing / Q000187:drug effects*
chemical_list: D000485:Allergens; D018926:Anti-Allergic Agents; D007485:Ioxaglic Acid